Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma

Annals of Surgical Oncology

Volumn 19, Issue 8, 2012, Pages 2563-2571

  Sharma, Ketan ^a   Beasley, Georgia ^a   Turley, Ryan ^a   Raymond, Amanda K ^a   Broadwater, Gloria ^a   Peterson, Bercedis ^a   Mosca, Paul ^a   Tyler, Douglas ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IN TRANSIT MELANOMA; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DACTINOMYCIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84865031036     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2315-5     Document Type: Article

References (31)

1. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: de Vita VT, Hellman S, Rosenberg SA, editors. Principles and Practice of Oncology. Philadelphia: JB Lippincott, 1993:1612-61.
2. CM Balch JE Gershenwald SJ Soong JF Thompson MB Atkins DR Byrd, et al. 2009 Final version of 2009 AJCC melanoma staging and classification J Clin Oncol. 27 6199 6206 19917835 10.1200/JCO.2009.23.4799
3. DR Minor RE Allen D Alberts YM Peng G Tardelli J Hutchinson 1985 A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma Cancer. 55 2638 2644 3995475 10.1002/1097-0142(19850601) 55:11<2638::AID-CNCR2820551118>3.0.CO;2-E 1:STN:280:DyaL2M3gtFentw%3D%3D
4. F Di Filippo A Calabro D Giannarelli S Carlini F Cavaliere F Moscarelli, et al. 1989 Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion Cancer. 63 2551 2561 2720604 10.1002/1097-0142(19890615)63:12<2551::AID-CNCR2820631233>3.0.CO;2-7
5. JM Klaase BB Kroon AN van Geel AM Eggermont HR Franklin AA Hart 1994 Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan Surgery. 115 39 45 8284759 1:STN:280: DyaK2c7ht1Kmtw%3D%3D
6. BB Kroon AN van Geel C Benckhuijsen J Wieberdink 1987 Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs Anticancer Res. 7 441 442 3631900 1:STN:280:DyaL2szisVOltA%3D%3D
7. AI Skene AS Bulman TR Williams JM Thomas G Westbury 1990 Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb Br J Surg. 77 765 767 2383752 10.1002/bjs.1800770716 1:STN:280:DyaK3czksFWktw%3D%3D
8. DL Fraker 2004 Management of in-transit melanoma of the extremity with isolated limb perfusion Curr Treat Options Oncol. 5 173 184 15115646 10.1007/s11864-004-0009-3
9. Fraker D, Eggermont A. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch C, Houghton A, Sober A, Soong S, editors. Cutaneous Melanoma. St. Louis: Quality Medical, 2003:405-18.
10. AK Raymond GM Beasley G Broadwater CK Augustine JC Padussis R Turley, et al. 2011 Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution J Am Coll Surg. 213 306 316 21493111 10.1016/j.jamcollsurg.2011.03. 013
11. GM Beasley A Caudle RP Petersen NS McMahon J Padussis PJ Mosca, et al. 2009 A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US J Am Coll Surg. 208 706 715 19476821 10.1016/j.jamcollsurg.2008.12.019 (discussion 715-7)
12. DW Siemann M Chapman A Beikirch 1991 Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy Int J Radiat Oncol Biol Phys. 20 287 289 1991690 10.1016/0360-3016(91)90106-E 1:STN:280:DyaK3M7itlWhuw%3D%3D
13. P Lindner A Doubrovsky PC Kam JF Thompson 2002 Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma Ann Surg Oncol. 9 127 136 11888868
14. HM Kroon M Moncrieff PC Kam JF Thompson 2008 Outcomes following isolated limb infusion for melanoma. A 14-year experience Ann Surg Oncol. 15 3003 3013 18509706 10.1245/s10434-008-9954-6
15. A Coleman CK Augustine G Beasley G Sanders D Tyler 2009 Optimizing regional infusion treatment strategies for melanoma of the extremities Expert Rev Anticancer Ther. 9 1599 1609 19895244 10.1586/era.09.126 1:CAS:528:DC%2BD1MXhtl2rsbrK
16. GM Beasley RP Petersen J Yoo N McMahon T Aloia W Petros, et al. 2008 Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion Ann Surg Oncol. 15 2195 2205 18528730 10.1245/s10434-008-9988-9
17. JF Thompson JA Hunt KF Shannon PC Kam 1997 Frequency and duration of remission after isolated limb perfusion for melanoma Arch Surg. 132 903 907 9267277 10.1001/archsurg.1997.01430320105017 1:STN:280:DyaK2svht1Khtw%3D%3D
18. HC Polk Jr MJ Edwards 1999 Post-perfusion recurrent melanoma Ann Surg Oncol. 6 524 10493618 10.1007/s10434-999-0524-3
19. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada J Natl Cancer Inst. 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
20. N McMahon TY Cheng GM Beasley I Spasojevic W Petros CK Augustine, et al. 2009 Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 16 953 961 19184236 10.1245/s10434-008-0288-1 1:STN:280: DC%2BD1M7ptFKrsg%3D%3D
21. GM Beasley N McMahon G Sanders CK Augustine MA Selim B Peterson, et al. 2009 A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma Cancer. 115 4766 4774 19637344 10.1002/cncr.24509 1:CAS:528: DC%2BD1MXhtlGns7nI
22. GM Beasley G Sanders N McMahon, et al. 2010 Final results of a prospective multi-center phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion (M-ILI) in patients with advanced extremity melanoma Ann Surg Oncol. 17 S21 10.1245/s10434-009-0763-3
23. McMahon N, Beasley GM, Sanders G, Augustine C, Padussis J, Coleman A, et al., A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma. J Clin Oncol. 2009;27:9065.
24. TA Aloia E Grubbs M Onaitis PJ Mosca TY Cheng H Seigler, et al. 2005 Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response Arch Surg. 140 1115 1120 16301451 10.1001/archsurg.140.11.1115
25. WR Cornett LM McCall RP Petersen MI Ross HA Briele RD Noyes, et al. 2006 Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020 J Clin Oncol. 24 4196 4201 16943537 10.1200/JCO.2005.05.5152 1:CAS:528:DC%2BD28XhtVantbvL
26. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc. 53 457 481 10.1080/01621459.1958.10501452
27. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Wiley Series in Probability and Mathematical Statistics. New York: Wiley, 1980.
28. AL Feldman HR Alexander Jr DL Bartlett DL Fraker SK Libutti 1999 Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma Ann Surg Oncol. 6 562 567 10493624 10.1007/s10434-999-0562-x 1:STN:280:DyaK1MvitFeltQ%3D%3D
29. A Sanki PC Kam JF Thompson 2007 Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology Ann Surg. 245 591 596 17414608 10.1097/01.sla.0000251746.02764.fc
30. KA Yao EC Hsueh R Essner LJ Foshag LA Wanek DL Morton 2003 Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg. 238 743 747 14578738 10.1097/01.sla.0000094440.50547.1d
31. GM Beasley JC Riboh CK Augustine JS Zager SN Hochwald SR Grobmyer, et al. 2011 Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma J Clin Oncol. 29 1210 1215 21343562 10.1200/JCO.2010.32.1224 1:CAS:528:DC%2BC3MXmtVyrsb4%3D